The paper presents a multimodal 3D convolutional neural network that classifies Alzheimer’s disease using raw OASIS 1 MRI volumes. It fuses structural T1 images with gray matter, white matter, and cerebrospinal fluid probability maps to capture complementary neuroanatomical information. Evaluated with 5‑fold subject‑level cross‑validation, the model achieves a mean accuracy of 72.34 % and an ROC AUC of 0.7781, with GradCAM visualizations highlighting anatomically relevant regions such as the medial temporal lobe and ventricles.
By Md Sifat, Sania Akter, Akif Islam, Md. Ekramul Hamid, Abu Saleh Musa Miah, Najmul Hassan, Md Abdur Rahim, Jungpil Shin
Deep learning models for neuroimaging have largely been developed for individual tasks, limiting knowledge transfer across applications. Here we introduce GenFAR, a modular deep learning framework that learns general, clinically informed features from brain MRIs.
BrainNorm is a normative foundation model trained on about 66,000 T1-weighted structural MRI scans. It uses language‑image style contrastive pretraining to create a Semantic Atlas Latent space (SAL), where each scan is encoded as atlas‑parcel embeddings that capture healthy aging trajectories. The model supports age‑consistent template matching, localized deviation scoring, and zero‑shot disease prediction, outperforming nine baselines across multiple downstream tasks and aligning its deviation patterns with known neurodegeneration pathology.
arXiv:2604. 27277v3 Announce Type: replace-cross Abstract: Brain MRI underpins a wide range of neuroscientific and clinical applications, yet most learning-based methods remain task-specific and require substantial labeled data.
By Yizhou Wu, Shansong Wang, Yuheng Li, Mojtaba Safari, Mingzhe Hu, Chih-Wei Chang, Harini Veeraraghavan, Xiaofeng Yang
arXiv:2506.15626v3 Announce Type: replace-cross
Abstract: $\textbf{Objective:}$ Brain-predicted age difference (BrainAGE) is a neuroimaging biomarker reflecting brain health. However, training robust...
By Vincent Roca, Marc Tommasi, Paul Andrey, Aur\'elien Bellet, Markus D. Schirmer, Hilde Henon, Laurent Puy, Julien Ramon, Gr\'egory Kuchcinski, Martin Bretzner, Renaud Lopes
arXiv:2504. 06299v2 Announce Type: replace-cross Abstract: Multimodal prediction models based on imaging and clinical data are increasingly used for clinical decision support, yet their interpretability remains limited.
By Lisa Herzog, Jonas Br\"andli, Maurice Schneeberger, Loran Avci, Nordin Dari, Martin H\"ansel, Hakim Baazaoui, Pascal B\"uhler, Susanne Wegener, Beate Sick
arXiv:2601. 20503v2 Announce Type: replace-cross Abstract: White matter hyperintensities (WMH) and ischaemic stroke lesions (ISL) are key imaging biomarkers of cerebral small vessel disease (SVD) detectable on magnetic resonance imaging (MRI).
By Jesse Phitidis, Alison Q. Smithard, William N. Whiteley, Joanna M. Wardlaw, Miguel O. Bernabeu, Maria Vald\'es Hern\'andez
arXiv:2607. 07091v1 Announce Type: cross Abstract: In longitudinal Alzheimer's disease (AD) diagnosis support, clinical and imaging information is often collected at irregular visits.
By Xinyue Du, Yibo Liu, Zhenglei Zhou, Xuancheng Yao, Weimin Zhong, Qiuhui Chen
arXiv:2606. 20037v1 Announce Type: new Abstract: Alzheimer's disease (AD) is an irreversible neurodegenerative disorder and a leading cause of death worldwide.
By Loukas Ilias, Anthi-Maria Vozinaki, Christos Ntanos, Dimitris Askounis
arXiv:2608. 08926v1 Announce Type: new Abstract: Neuroimaging and genetic testing are two important clinical references for nervous system diseases, offering complementary diagnostic information.
By Tianli Tao, Ziyang Wang, Emma Robinson, Rachel Sparks, Le Zhang
arXiv:2606. 01237v1 Announce Type: new Abstract: Mild cognitive impairment (MCI) and subjective cognitive decline (SCD) are closely associated with the early Alzheimer's disease continuum, where accurate and explainable diagnosis is important for early risk assessment and intervention.
By Xiongri Shen, Jiaqi Wang, Zhenxi Song, Yi Zhong, Leilei Zhao, Xin He, Baiying Lei, Zhiguo Zhang
The paper introduces MCNet, a neural network that assigns a Modality Contribution Score (MCS) to each patient, indicating how much structural MRI versus amyloid PET drives the diagnostic decision for Alzheimer’s disease. Across 327 ADNI-3 participants, MCNet achieved strong three‑class staging (AUC = 0.881) and the MCS showed a clear, statistically significant increase in PET dominance from cognitively normal to AD. The method was validated on an independent OASIS‑3 cohort and compared favorably to SHAP, suggesting it can guide personalized imaging and clinical trial decisions.
By Dawa Chyophel Lepcha, Aaliya Ali, Sophie A. Martin, Deepika Koundal, Pierrick Coupe, Shabbir Syed-Abdul